【我的总结与翻译】

总结：inhibitor,

A study has raised new questions about the effectiveness of several popular drugs for depression. These antidepressants are known as selective (serotonin) reuptake (inhibitors).

一项研究引发了对一些有关几种常用治疗忧郁症药物疗效的新质疑。这些抗忧郁症药物就是选择性5-HT再摄取抑制剂。

S.S.R.I.s are designed to help keep (serotonin), a brain chemical, at a continuous level. The new study suggests that they provide little help to the large majority of the millions who take them. Scientists from Britain, Canada and the United States did the study. It was a (meta)-analysis, a study of studies.

选择性5-HT再摄取抑制剂的发明有助于5-羟色胺（一种大脑中的化学物质）保持持续的水平。新的研究表明，他们对数百万服用这些药物的绝大多数人提供的帮助很少。来自英国、加拿大以及美国的科学家对此进行了研究，这就是荟萃分析，基于很多研究的一项研究。

The team used an American law, the Freedom of Information Act, to get unpublished reports on 35 clinical trials of 4 drugs. Drug companies gave these and published studies to the Food and Drug Administration for approval of the medicines. In the clinical trials, people with depression were treated with either an antidepressant or a placebo, a pill that contains no medicine. They did not know which they got.

该科学小组利用美国的一项法律，即《信息自由法案》，获得了未出版的4种药物的35个临床试验报告。药品公司提供了这些报告，并将这些研究出版，以使得食品和药物管理局正式批准这些药物的生产。在临床试验中，部分忧郁症的患者服用抗忧郁药或是安慰剂来治疗，安慰剂是一种不含药物的片剂。而患者并不知道他们服用的是哪一种。

The new report says those who received medicine did improve. But comparable numbers of those who received placebos also improved. The report says the drugs had meaningful results only in the most severely depressed patients.

新的报告指出，那些服用药物的患者情况确实有所改善。但相比较，那些服用安慰剂的患者情况同样也有所好转。该报告称，药物仅对那些严重忧郁症的患者才有显著的疗效。